Anti-GD3 Antibody

<strong>Anti-GD3 Antibody </strong>_x000D_ <strong>Catalog number:</strong> B2014986_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -80°C_x000D_ <strong>Keywords:</strong> Anti-GD3 Monoclonal Antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Cheung IY, Cheung NV, Modak S, Mauguen A, Feng Y, Basu E, Roberts SS, Ragupathi G, Kushner BH. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression J Clin Oncol. 2021 Jan 20;39(3):215-226._x000D_ 2: Chapman PB. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody Curr Opin Investig Drugs. 2003 Jun;4(6):710-5._x000D_ 3: Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry R, LoBuglio AF, Forero A. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity Cancer Biother Radiopharm. 2006 Dec;21(6):553-60._x000D_ 4: Ojima F, Ido T, Kijima-Suda I, Nakagawa Y. Biodistribution study of murine monoclonal anti-GD3 antibody in nude mice bearing human melanoma xenografts for development of immunoscintigraphy Tohoku J Exp Med. 1998 Jun;185(2):89-100._x000D_ 5: Reaman GH, Taylor BJ, Merritt WD. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis Cancer Res. 1990 Jan 1;50(1):202-5._x000D_ 6: Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside Clin Cancer Res. 2004 Jul 15;10(14):4717-23._x000D_ 7: Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside Vaccine. 2004 Jul 29;22(21-22):2904-9._x000D_ 8: Hedberg KM, Dellheden B, Wikstrand CJ, Fredman P. Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro Glycoconj J. 2000 Oct;17(10):717-26._x000D_ 9: Chapman PB, Lonberg M, Houghton AN. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity Cancer Res. 1990 Mar 1;50(5):1503-9._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/9816218">10: McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant Clin Cancer Res. 1996 Apr;2(4):679-86.</a>_x000D_ _x000D_ <strong>Products Related to Anti-GD3 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>